|
EP2210607B1
(en)
*
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
US7531532B2
(en)
|
2004-02-27 |
2009-05-12 |
Eisai R&D Management Co., Ltd. |
Pyridine derivative and pyrimidine derivative
|
|
ES2438017T3
(es)
|
2004-07-30 |
2014-01-15 |
Methylgene Inc. |
Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
|
|
KR101378716B1
(ko)
*
|
2005-05-20 |
2014-04-10 |
메틸진 인코포레이티드 |
Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
|
|
AU2006313456B2
(en)
|
2005-05-20 |
2011-06-23 |
Methylgene Inc. |
Inhibitors of VEGF receptor and HGF receptor signaling
|
|
CA2607699A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Galaxy Biotech, Llc |
Methods of treating brain tumors with antibodies
|
|
CN101198590B
(zh)
|
2005-08-24 |
2012-05-09 |
卫材R&D管理有限公司 |
吡啶衍生物及嘧啶衍生物（3）
|
|
PT1940844E
(pt)
*
|
2005-10-28 |
2010-01-06 |
Scripps Research Inst |
Compostos e composições como inibidores de proteína-quinase
|
|
NL2000291C2
(nl)
|
2005-11-10 |
2009-02-17 |
Pfizer Prod Inc |
1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
|
|
JP2009526761A
(ja)
|
2006-01-30 |
2009-07-23 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環式チオフェン化合物および使用の方法
|
|
WO2007103308A2
(en)
|
2006-03-07 |
2007-09-13 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
|
AR059922A1
(es)
*
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
|
CA2651898A1
(en)
|
2006-04-07 |
2007-10-18 |
Develogen Aktiengesellschaft |
Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
|
|
JP2009539878A
(ja)
*
|
2006-06-08 |
2009-11-19 |
アレイ バイオファーマ、インコーポレイテッド |
キノリン化合物および使用方法
|
|
EP1889847A1
(en)
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidines for pharmaceutical compositions
|
|
EP2057164A1
(en)
|
2006-08-07 |
2009-05-13 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
CA2661333C
(en)
*
|
2006-08-23 |
2014-08-05 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
JP2010507618A
(ja)
*
|
2006-10-27 |
2010-03-11 |
グラクソ グループ リミテッド |
ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
|
|
RS54510B1
(sr)
|
2006-11-22 |
2016-06-30 |
Incyte Holdings Corporation |
Imidazotriazini i imidazopirimidini kao inhibitori kinaze
|
|
NZ577197A
(en)
|
2006-12-08 |
2011-02-25 |
Irm Llc |
Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
CN101918403A
(zh)
*
|
2007-09-06 |
2010-12-15 |
阵列生物制药公司 |
作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
NZ588355A
(en)
|
2008-03-05 |
2012-03-30 |
Methylgene Inc |
Inhibitors of protein tyrosine kinase activity
|
|
TWI472529B
(zh)
|
2008-05-21 |
2015-02-11 |
Incyte Corp |
２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
|
|
KR101335843B1
(ko)
*
|
2008-08-20 |
2013-12-02 |
조에티스 엘엘씨 |
피롤로[2,3-ｄ]피리미딘 화합물
|
|
UY32072A
(es)
|
2008-08-26 |
2010-03-26 |
Boehringer Ingelheim Int |
Tienopirimidinas para composiciones farmacéuticas
|
|
ES2599458T3
(es)
*
|
2008-10-14 |
2017-02-01 |
Sunshine Lake Pharma Co., Ltd. |
Compuestos y métodos de uso
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
EP2408300B1
(en)
*
|
2009-03-21 |
2016-05-11 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
|
EP2245936A1
(en)
|
2009-04-27 |
2010-11-03 |
Bayer CropScience AG |
Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
ES2426407T3
(es)
*
|
2009-10-15 |
2013-10-23 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
UY33241A
(es)
|
2010-02-26 |
2011-09-30 |
Boehringer Ingelheim Int |
?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
|
|
MX2012009851A
(es)
|
2010-02-26 |
2012-09-12 |
Boehringer Ingelheim Int |
Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
|
|
JP5575274B2
(ja)
|
2010-02-26 |
2014-08-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
|
|
NZ604306A
(en)
|
2010-05-17 |
2015-02-27 |
Incozen Therapeutics Pvt Ltd |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
US9073918B2
(en)
|
2010-05-20 |
2015-07-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
MX2013012695A
(es)
|
2011-05-02 |
2014-03-27 |
Exelixis Inc |
Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
|
|
US8772277B2
(en)
|
2011-08-04 |
2014-07-08 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
EP2758402B9
(en)
|
2011-09-22 |
2016-09-14 |
Pfizer Inc |
Pyrrolopyrimidine and purine derivatives
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013106792A1
(en)
|
2012-01-13 |
2013-07-18 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
CN107082779A
(zh)
|
2012-03-30 |
2017-08-22 |
理森制药股份公司 |
作为c‑met 蛋白激酶调节剂的新化合物
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
CN104507930B
(zh)
*
|
2012-06-29 |
2017-10-10 |
贝达药业股份有限公司 |
作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
|
|
TWI520962B
(zh)
*
|
2012-06-29 |
2016-02-11 |
|
As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
|
|
CN103570723B
(zh)
*
|
2012-07-27 |
2016-07-13 |
广西梧州制药（集团）股份有限公司 |
吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
|
|
AU2013343105B2
(en)
|
2012-11-08 |
2016-04-14 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine D1 ligands
|
|
CN102964308B
(zh)
*
|
2012-11-30 |
2015-03-18 |
中国药科大学 |
新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
WO2014165779A1
(en)
*
|
2013-04-04 |
2014-10-09 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
KR102173433B1
(ko)
|
2013-07-11 |
2020-11-04 |
에이시아 바이오사이언시스 인코포레이티드. |
키나아제 억제제로써의 피리미딘 유도체
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
|
WO2015162515A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EP3134405B1
(en)
|
2014-04-25 |
2019-08-28 |
Pfizer Inc |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
EP3292115B1
(en)
*
|
2015-07-20 |
2019-12-25 |
Betta Pharmaceuticals Co., Ltd. |
Crystalline form of fused pyridine derivative's maleate and uses thereof
|
|
CA3030582A1
(en)
|
2015-07-22 |
2017-01-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Compounds and uses thereof in the treatment of cancers and other medical conditions
|
|
US12220398B2
(en)
|
2015-08-20 |
2025-02-11 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
JP6889494B2
(ja)
|
2015-10-09 |
2021-06-18 |
エイシア セラピューティクス， インコーポレイテッド |
ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
|
|
GB201520499D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
GB201520500D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
|
EP3442531A1
(en)
|
2016-04-15 |
2019-02-20 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
|
|
CN106496232B
(zh)
*
|
2016-09-22 |
2018-11-09 |
南方医科大学 |
一种具有抗肿瘤活性的1-(2-四氢吡喃)-1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3638670B1
(en)
|
2017-06-13 |
2021-07-21 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CA3070013A1
(en)
|
2017-07-18 |
2019-01-24 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
TWI831259B
(zh)
|
2018-06-15 |
2024-02-01 |
漢達生技醫藥股份有限公司 |
包含達沙替尼十二烷基硫酸鹽組合物的膠囊
|
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
|
WO2020120257A1
(en)
|
2018-12-11 |
2020-06-18 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2020132384A1
(en)
|
2018-12-21 |
2020-06-25 |
Celgene Corporation |
Thienopyridine inhibitors of ripk2
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
CN114466847A
(zh)
*
|
2019-06-25 |
2022-05-10 |
西诺普塞疗法公司 |
用于治疗癌症的化合物
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN116836176B
(zh)
*
|
2022-03-23 |
2026-02-24 |
中国科学院上海药物研究所 |
青蒿素类化合物、其制备方法和应用
|
|
CN115160340B
(zh)
*
|
2022-06-07 |
2023-07-21 |
四川大学华西医院 |
一种具有ack1抑制活性的小分子化合物及其应用
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
US20260049059A1
(en)
*
|
2022-11-25 |
2026-02-19 |
Synthon B.V. |
A process for preparation of cabozantinib or tivozanib
|
|
WO2024163400A1
(en)
|
2023-01-31 |
2024-08-08 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|